Lung Cancer
Conditions
Interventions
Exposed group (combination chemotherapy):EGFR-TKI administered concurrently or sequentially with platinum-based doublet chemotherapy:None
Unexposed group (monotherapy): EGFR-TKI monotherapy alone:None
Sponsors
Second Affiliated Hospital of Army Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Age 18–80 years; 2. Pathologically confirmed EGFR-sensitive mutation (19del/L858R) via biopsy; 3. Clinical stage II–IIIB (AJCC 8th edition), assessed as surgically resectable by a multidisciplinary team (MDT); 4. Treatment regimen: (1) Monotherapy group received >=2 cycles of neoadjuvant EGFR-TKI monotherapy (osimertinib/erlotinib/gefitinib); (2) Combination group received >=2 cycles of neoadjuvant EGFR-TKI plus platinum-based doublet chemotherapy (e.g., pemetrexed + cisplatin); 5. Surgical completion: Underwent radical resection (R0/R1) with evaluable pathological specimens.
Exclusion criteria
Exclusion criteria: 1. Concurrent mutations in other driver genes (e.g., ALK, ROS1, RET, etc.); 2. Disease progression (PD) during neoadjuvant therapy or failure to undergo surgery; 3. Prior history of chest radiotherapy or immunotherapy; 4. Incomplete clinical data (e.g., missing baseline imaging or pathology reports).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MPR, Major Pathological Response;Survival status (Overall Survival, Event-Free Survival); | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathologic Complete Response;Drug regimen (targeted therapy, chemotherapy regimen, and treatment duration);Site and time of recurrence;Adverse events (incidence of grade >=3 immune-related adverse events [irAEs], surgical complications [Clavien-Dindo classification]); | — |
Countries
China
Contacts
Public ContactChen Liang
Second Affiliated Hospital of Army Medical University, PLA
Outcome results
None listed